Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1Phase 1 1

Status

Unknown 4Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 49Thoracic 28Head & Neck 12Genitourinary 7Breast 7Other solid neoplasm 6Lymphoid 6Tumor-Agnostic 5Sarcoma 5Gynecologic 4Dermatologic 3Other hematologic neoplasm 2Myeloid 1CNS 1

Conditions

Sarcoma 3Chondrosarcoma 2Uterine Neoplasms 1Osteosarcoma 1Neoplasms 1Adenoviridae Infections 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT05193188 2023-02-16

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
70 enrolled
Sarcoma

Chondrosarcoma

NCT04606108 2020-10-28

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown
62 enrolled
Sarcoma

Sarcoma

NCT04294511 2020-03-04

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Sun Yat-sen University

Phase 2 Unknown
75 enrolled
Sarcoma

Osteosarcoma

NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Hunan Cancer Hospital

Phase 2 Unknown
120 enrolled
GynecologicSarcoma

Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡